NCT01695759 - Clinical Efficacy of Two Erythropoietin Drug in Participants With Secondary Anemia to Chronic Kidney Disease. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

December 31, 2014

Study Completion Date

January 31, 2018

Conditions

Chronic Kidney DiseaseAnemia

Interventions

DRUG

Epoetin alpha

Participants assigned to this arm will receive two subcutaneous administrations per week of 50 UI/kg of Epoetin alpha (Eritromax), totaling 100 UI/kg/week. After the first four weeks of treatment, once a month throughout the study the medication dose can be adjusted by the study Investigator according to the laboratory results.

DRUG

Eprex

Participants assigned to this arm will receive two subcutaneous administrations per week of 50 UI/kg of Epoetin alpha (Eprex), totaling 100 UI/kg/week. After the first four weeks of treatment, once a month throughout the study the medication dose can be adjusted by the study Investigator according to the laboratory results.

Trial Locations (10)

44001-584

Clínica Senhor do Bomfim Ltda, Feira de Santana

Unknown

Instituto Scribner de Ensino, Pesquisa, Ciência e Tecnologia, Curitiba

Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre

União Brasileira de Educação e Assistência Hospital São Lucas da PUCRS, Porto Alegre

Fundação Pró-Rim, Joinville

Hospital de Ensino Padre Anchieta, São Bernardo do Campo

Fundação Oswaldo Cruz (Hospital do Rim e Hipertensão), São Paulo

Real e Benemérita Associação Portuguesa de Beneficência São Paulo (Hospital Beneficência Portuguesa), São Paulo

95070-561

Fundação Universitária de Caxias do Sul - Instituto de Pesquisa Clínica para Estudos Multicêntricos, Caxias do Sul

05001-000

CMIN - Clínica De Medicina Interna E Nefrologia, São Paulo